Resveratrol downregulates Cyp2e1 and attenuates chemically induced hepatocarcinogenesis in SD rats

Journal of Toxicologic Pathology

Volumn 26, Issue 4, 2013, Pages 385-392

  Wu, Xiongfei ^a   Li, Chenggang ^a   Xing, Guozhen ^a   Qi, Xinming ^a   Ren, Jin ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cyp2e1; GST P; Hepatocarcinogenesis; Laser microdissection; Resveratrol

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B1; CYTOCHROME P450 2E1; CYTOCHROME P450 3A1; DIALLYL DISULFIDE; DIETHYLNITROSAMINE; GLUTATHIONE TRANSFERASE; N (2 FLUORENYL)ACETAMIDE; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; LIVER CARCINOGENESIS; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT; TISSUE SECTION; WESTERN BLOTTING;

EID: 84891397021     PISSN: 09149198     EISSN: None     Source Type: Journal    
DOI: 10.1293/tox.2013-0020     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D. Global cancer statistics. CA Cancer J Clin. 61: 69-90. 2011. [Medline] [CrossRef]
2. Thorgeirsson SS, and Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 31: 339-346. 2002. [Medline] [CrossRef]
3. Llovet JM, Burroughs A, and Bruix J. Hepatocellular carcinoma. Lancet. 362: 1907-1917. 2003. [Medline] [CrossRef]
4. Yates MS, and Kensler TW. Keap1 eye on the target: chemoprevention of liver cancer. Acta Pharmacol Sin. 28: 1331-1342. 2007. [Medline] [CrossRef]
5. Kensler TW, Qian GS, Chen JG, and Groopman JD. Translational strategies for cancer prevention in liver. Nat Rev Cancer. 3: 321-329. 2003. [Medline] [CrossRef]
6. Doll R, and Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 66: 1191-1308. 1981. [Medline]
7. Ogiso T, Tatematsu M, Tamano S, Hasegawa R, and Ito N. Correlation between medium-term liver bioassay system data and results of long-term testing in rats. Carcinogenesis. 11: 561-566. 1990. [Medline] [CrossRef]
8. Ito N, Tatematsu M, Hasegawa R, and Tsuda H. Mediumterm bioassay system for detection of carcinogens and modifiers of hepatocarcinogenesis utilizing the GST-P positive liver cell focus as an endpoint marker. Toxicol Pathol. 17: 630-641. 1989. [Medline]
9. Kang JS, Wanibuchi H, Morimura K, Gonzalez FJ, and Fukushima S. Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Cancer Res. 67: 11141-11146. 2007. [Medline] [CrossRef]
10. Timofeeva OA, Filipenko ML, Rychkova NA, Gulyaeva LF, and Lyakhovich VV. Expression of CYP1A in liver of A/ Sn and CC57BR mice differing in sensitivity to hepatocarcinogenesis induced by o-aminoazotoluene. Biochemistry (Mosc). 65: 718-722. 2000. [Medline]
11. Dewa Y, Nishimura J, Muguruma M, Jin M, Saegusa Y, Okamura T, Tasaki M, Umemura T, and Mitsumori K. beta-Naphthoflavone enhances oxidative stress responses and the induction of preneoplastic lesions in a diethylnitrosamineinitiated hepatocarcinogenesis model in partially hepatectomized rats. Toxicology. 244: 179-189. 2008. [Medline] [CrossRef]
12. Wang Y, Millonig G, Nair J, Patsenker E, Stickel F, Mueller S, Bartsch H, and Seitz HK. Ethanol-induced cytochrome P4502E1 causes carcinogenic etheno-DNA lesions in alcoholic liver disease. Hepatology. 50: 453-461. 2009. [Medline] [CrossRef]
13. Mbimba T, Awale P, Bhatia D, Geldenhuys WJ, Darvesh AS, Carroll RT, and Bishayee A. Alteration of hepatic proinflammatory cytokines is involved in the resveratrolmediated chemoprevention of chemically-induced hepatocarcinogenesis. Curr Pharm Biotechnol. 13: 229-234. 2012. [Medline] [CrossRef]
14. Bishayee A, Barnes KF, Bhatia D, Darvesh AS, and Carroll RT. Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prev Res (Phila). 3: 753-763. 2010. [Medline] [CrossRef]
15. Bishayee A, Waghray A, Barnes KF, Mbimba T, Bhatia D, Chatterjee M, and Darvesh AS. Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm Res. 27: 1080-1091. 2010. [Medline] [CrossRef]
16. Bishayee A, and Dhir N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact. 179: 131-144. 2009. [Medline] [CrossRef]
17. Aziz MH, Kumar R, and Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol. 23: 17-28. 2003. [Medline]
18. Beedanagari SR, Bebenek I, Bui P, and Hankinson O. Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. Toxicol Sci. 110: 61-67. 2009. [Medline] [CrossRef]
19. Mikstacka R, Przybylska D, Rimando AM, and Baer-Dubowska W. Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers. Mol Nutr Food Res. 51: 517-524. 2007. [Medline] [CrossRef]
20. Huynh HT, and Teel RW. Effects of plant-derived phenols on rat liver cytochrome P450 2B1 activity. Anticancer Res. 22: 1699-1703. 2002. [Medline]
21. Mikstacka R, Rimando AM, Szalaty K, Stasik K, and Baer-Dubowska W. Effect of natural analogues of trans-resveratrol on cytochromes P4501A2 and 2E1 catalytic activities. Xenobiotica. 36: 269-285. 2006. [Medline] [CrossRef]
22. Mikstacka R, Rimando AM, Dutkiewicz Z, Stefanski T, and Sobiak S. Design, synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1. Bioorg Med Chem. 20: 5117-5126. 2012. [Medline] [CrossRef]
23. Zhang CL, Zeng T, Zhao XL, and Xie KQ. Garlic oil attenuated nitrosodiethylamine-induced hepatocarcinogenesis by modulating the metabolic activation and detoxification enzymes. Int J Biol Sci. 9: 237-245. 2013. [Medline] [Cross-Ref]
24. Ye Q, Lian F, Chavez PR, Chung J, Ling W, Qin H, Seitz HK, and Wang XD. Cytochrome P450 2E1 inhibition prevents hepatic carcinogenesis induced by diethylnitrosamine in alcohol-fed rats. Hepatobiliary Surg Nutr. 1: 5-18. 2012. [Medline]
25. Liu LL, Gong LK, Qi XM, Cai Y, Wang H, Wu XF, Xiao Y, and Ren J. Altered expression of cytochrome P450 and possible correlation with preneoplastic changes in early stage of rat hepatocarcinogenesis. Acta Pharmacol Sin. 26: 737-744. 2005. [Medline] [CrossRef]
26. Márquez-Rosado L, Trejo-Solis C, Cabrales-Romero Mdel P, Arce-Popoca E, Sierra-Santoyo A, Alemán-Lazarini L, Fatel-Fazenda S, Carrasco-Legleu CE, and Villa-Treviño S. Co-carcinogenic effect of cyclohexanol on the development of preneoplastic lesions in a rat hepatocarcinogenesis model. Mol Carcinog. 46: 524-533. 2007. [Medline] [CrossRef]
27. Kushida M, Wanibuchi H, Morimura K, Kinoshita A, Kang JS, Puatanachokchai R, Wei M, Funae Y, and Fukushima S. Dose-dependence of promotion of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline-induced rat hepatocarcinogenesis by ethanol: evidence for a threshold. Cancer Sci. 96: 747-757. 2005. [Medline] [CrossRef]
28. Suzuki S, Asamoto M, Tsujimura K, and Shirai T. Specific differences in gene expression profile revealed by cDNA microarray analysis of glutathione S-transferase placental form (GST-P) immunohistochemically positive rat liver foci and surrounding tissue. Carcinogenesis. 25: 439-443. 2004. [Medline] [CrossRef]
29. Cullen JJ, Mitros FA, and Oberley LW. Expression of antioxidant enzymes in diseases of the human pancreas: another link between chronic pancreatitis and pancreatic cancer. Pancreas. 26: 23-27. 2003. [Medline] [CrossRef]
30. Matés JM, Pérez-Gómez C, and Núnéz de Castro I. Antioxidant enzymes and human diseases. Clin Biochem. 32: 595-603. 1999. [Medline] [CrossRef]
31. Leung TM, and Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol. 58: 395-398. 2013. [Medline] [CrossRef]
32. Schattenberg JM, Wang Y, Rigoli RM, Koop DR, and Czaja MJ. CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. Hepatology. 39: 444-455. 2004. [Medline] [CrossRef]
33. Pastrakuljic A, Tang BK, Roberts EA, and Kalow W. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol. 53: 531-538. 1997. [Medline] [CrossRef]
34. Santostefano M, Merchant M, Arellano L, Morrison V, Denison MS, and Safe S. alpha-Naphthoflavone-induced CYP1A1 gene expression and cytosolic aryl hydrocarbon receptor transformation. Mol Pharmacol. 43: 200-206. 1993. [Medline]
35. Hayashi H, Taniai E, Morita R, Yafune A, Suzuki K, Shibutani M, and Mitsumori K. Threshold dose of liver tumor promoting effect of beta-naphthoflavone in rats. J Toxicol Sci. 37: 517-526. 2012. [Medline] [CrossRef]
36. Suzuki S, Takeshita K, Doi Y, Asamoto M, Takahashi S, Naiki-Ito A, and Shirai T. 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)-induced hepatocarcinogenesis is not enhanced by CYP1A inducers, alpha-and beta-naphthoflavone: relationship to intralobular distribution of CYP1A expression. Toxicol Pathol. 38: 583-591. 2010. [Medline] [CrossRef]
37. Kuribayashi M, Asamoto M, Suzuki S, Hokaiwado N, Ogawa K, and Shirai T. Lack of modification of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) rat hepatocarcinogenesis by caffeine, a CYP1A2 inducer, points to complex counteracting influences. Cancer Lett. 232: 289-299. 2006. [Medline] [CrossRef]
38. Suzuki S, Takahashi S, Asamoto M, Inaguma S, Ogiso T, Hirose M, and Shirai T. Lack of modification of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx)-induced hepatocarcinogenesis in rats by fenbendazole--a CYP1A2 inducer. Cancer Lett. 185: 39-45. 2002. [Medline] [CrossRef]